Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cancer cell senescence: a new frontier in drug development.
Cairney CJ, Bilsland AE, Evans TR, Roffey J, Bennett DC, Narita M, Torrance CJ, Keith WN. Cairney CJ, et al. Among authors: torrance cj. Drug Discov Today. 2012 Mar;17(5-6):269-76. doi: 10.1016/j.drudis.2012.01.019. Epub 2012 Jan 31. Drug Discov Today. 2012. PMID: 22314100 Review.
A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds.
Cairney CJ, Godwin LS, Bilsland AE, Burns S, Stevenson KH, McGarry L, Revie J, Moore JD, Wiggins CM, Collinson RS, Mudd C, Tsonou E, Sadaie M, Bennett DC, Narita M, Torrance CJ, Keith WN. Cairney CJ, et al. Among authors: torrance cj. PLoS Genet. 2017 Aug 14;13(8):e1006942. doi: 10.1371/journal.pgen.1006942. eCollection 2017 Aug. PLoS Genet. 2017. PMID: 28806777 Free PMC article.
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, Shokat KM, Bandyopadhyay S, Lord CJ, Ashworth A. Miller RE, et al. Among authors: torrance c. Mol Cancer Ther. 2016 Jul;15(7):1472-84. doi: 10.1158/1535-7163.MCT-15-0554. Epub 2016 Jun 30. Mol Cancer Ther. 2016. PMID: 27364904
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A. Costa-Cabral S, et al. Among authors: torrance c. PLoS One. 2016 Feb 16;11(2):e0149099. doi: 10.1371/journal.pone.0149099. eCollection 2016. PLoS One. 2016. PMID: 26881434 Free PMC article.
Target identification for small-molecule discovery in the FOXO3a tumor-suppressor pathway using a biodiverse peptide library.
Emery A, Hardwick BS, Crooks AT, Milech N, Watt PM, Mithra C, Kumar V, Giridharan S, Sadasivam G, Mathivanan S, Sudhakar S, Bairy S, Bharatham K, Hurakadli MA, Prasad TK, Kamariah N, Muellner M, Coelho M, Torrance CJ, McKenzie GJ, Venkitaraman AR. Emery A, et al. Among authors: torrance cj. Cell Chem Biol. 2021 Nov 18;28(11):1602-1615.e9. doi: 10.1016/j.chembiol.2021.05.009. Epub 2021 Jun 9. Cell Chem Biol. 2021. PMID: 34111400 Free PMC article.
Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.
Narvaez AJ, Ber S, Crooks A, Emery A, Hardwick B, Guarino Almeida E, Huggins DJ, Perera D, Roberts-Thomson M, Azzarelli R, Hood FE, Prior IA, Walker DW, Boyce R, Boyle RG, Barker SP, Torrance CJ, McKenzie GJ, Venkitaraman AR. Narvaez AJ, et al. Among authors: torrance cj. Cell Chem Biol. 2017 Aug 17;24(8):1017-1028.e7. doi: 10.1016/j.chembiol.2017.07.009. Epub 2017 Aug 10. Cell Chem Biol. 2017. PMID: 28807782 Free PMC article.
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A. Costa-Cabral S, et al. Among authors: torrance c. PLoS One. 2016 Apr 18;11(4):e0154007. doi: 10.1371/journal.pone.0154007. eCollection 2016. PLoS One. 2016. PMID: 27088596 Free PMC article. No abstract available.
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A. Costa-Cabral S, et al. Among authors: torrance c. PLoS One. 2017 Apr 20;12(4):e0176578. doi: 10.1371/journal.pone.0176578. eCollection 2017. PLoS One. 2017. PMID: 28426773 Free PMC article.
Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A. Costa-Cabral S, et al. Among authors: torrance c. PLoS One. 2018 Oct 26;13(10):e0206729. doi: 10.1371/journal.pone.0206729. eCollection 2018. PLoS One. 2018. PMID: 30365555 Free PMC article.
30 results